Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Mississippi for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Mississippi only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Mississippi (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Justin Baker (NPI 1639119589)

Field	Value
Entity Type	Individual
Organization	Justin Baker
Address	1227 N State St Ste 101
City	Jackson
State	MS
ZIP	39202
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	June 8, 2006

Payer Source	Total Paid
Medicare	$4.1M
Medicaid	$0

Key Findings

This provider is highly focused on oncology infusion services: the largest revenue codes are oncology biologic infusions (J9271, J9299, J0897) and chemotherapy administration codes (96413, 96401, 96365), indicating the practice primarily delivers systemic cancer therapies and supportive oncology injections rather than being a general primary-care office. The prominence of J9271 (pembrolizumab) and J9299 (nivolumab) combined with multiple chemotherapy administration codes supports a service-line oriented around immune checkpoint inhibitors and IV chemotherapy delivery.

Medicare revenue is the sole recorded public-payer footprint for this provider: total Medicare revenue is $4.1M while there is no Medicaid billing on file, so the entity operates effectively as a single-payer (Medicare) biller in the datasets provided. That concentration suggests Medicare dominates public reimbursement exposure and network/contracting considerations for this provider.

Revenue concentration is highly focused: the precomputed top three Medicare codes by revenue account for 81.6% of the provider’s total Medicare revenue, with J9271 alone representing $2.2M (54.6% of Medicare revenue). This concentration implies the practice’s financial performance is heavily dependent on a small set of high-cost oncology injections rather than broad ancillary or E/M services.

The provider is a national outlier on certain high-cost immunotherapy codes: J9271 ranks #11 of 1841 providers nationally and is labeled an "extreme outlier," placing this clinician among the very highest-volume billers of pembrolizumab in the country. J9299 ranks in the 91st percentile nationally and is a high-volume contributor as well, indicating the provider has above-typical scale for immune checkpoint inhibitor administration compared with peers.

There are additional above-typical volumes on other injectable agents: J0897 (denosumab) is listed as "notably above typical" and ranks #437 of 10057 providers, and J2506 (pegfilgrastim) ranks in the 97th percentile. These placements indicate the practice also provides supportive cancer care and bone-modifying therapy at volumes well above most clinicians, reinforcing an oncology infusion center profile with broad supportive-service utilization.

Although infusion/injectable drug codes dominate revenue, the provider also bills non-drug oncology services and diagnostics at above-typical levels: E/M code 99214 generates $130K (3.2% of Medicare revenue) and comprehensive labs such as 80053 and 85025 appear in the top codes with high national percentile ranks. This mix suggests on-site evaluation and diagnostic monitoring are integrated into the clinician’s outpatient oncology workflow rather than being outsourced.

Clinical tenure is long-standing: the NPI was enumerated on 2006-06-08 (approximately 20 years ago), indicating the provider has an established presence and likely sustained referral relationships and operational infrastructure to support high-volume infusion care. That longevity helps explain the scale seen in high-volume oncology drug billing.

Given the relative rankings, the provider is a dominant national participant for select drugs but otherwise a strong regional/high-volume oncology clinician: codes like J9311 (rituximab with hyaluronidase) rank #3 of 5 providers (a small-number specialty ranking) and several lab and E/M codes fall into high percentiles (often 90th+). Taken together, this pattern signals dominance on a narrow set of high-value oncology injectables with broadly above-typical utilization of related supportive and monitoring services.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

66 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	56,000	$40	$2.2M
J9299	Injection, nivolumab, 1 mg	35,200	$20	$844.8K
J0897	Injection, denosumab, 1 mg	16,440	$20	$263K
J9311	Injection, rituximab 10 mg and hyaluronidase	7,080	$30	$205.3K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,530	$90	$130K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	1,150	$80	$91K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	790	$80	$65.6K
J1439	Injection, ferric carboxymaltose, 1 mg	52,500	$1	$52.5K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	520	$60	$29.8K
80053	The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel.	2,280	$10	$22.8K

Showing 1–10 of 66

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 66 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Mississippi Distribution

Justin Baker — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Mississippi

Full comparison — all codes billed, vs. state median

66 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	1	10	16,700	$40	$1M
J9299	3	10	21,120	$20	$569.7K
J9311	2	10	7,080	$30	$195.5K
J0897	5	110	3,030	$20	$95.7K
J2506	4	10	910	$80	$91.5K
J1439	7	20	42,000	$1	$41.6K
J3315	2	10	120	$300	$35.5K
J0185	5	10	18,330	$1	$26.4K
96413	5	70	100	$80	$22.6K
99214	68	4,110	170	$70	$21.9K

Showing 1–10 of 66

Related Providers

Other providers that share a Tax Identification Number (TIN) with Justin Baker, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Guangzhi Qu	MS	Hematology & Oncology Physician	$9.1M	$0
Tammy Young	MS	Medical Oncology Physician	$5.1M	$0
Nicole Cleveland	MS	Medical Oncology Physician	$2.8M	$0
Thomas Williamson	NC	Hematology & Oncology Physician	$2.4M	$0
Manubhai Patel	MS	Medical Oncology Physician	$1.9M	$0
Elizabeth Herrington	MS	Medical Oncology Physician	$1.9M	$0
Natale Sheehan	MS	Medical Oncology Physician	$1.4M	$0
Bobby Graham	MS	Hospice and Palliative Medicine (Internal Medicine) Physician	$143.8K	$0
Donald Tisdale	MS	Family Nurse Practitioner	$113.4K	$0
Meaghan Johnson	MS	Family Nurse Practitioner	$98.5K	$0

Nearby Providers

Other providers in the same ZIP code as Justin Baker, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mississippi Behavioral Health Services, LLC	MS	Community/Behavioral Health Agency	$0	$72.8M
Mississippi Baptist Medical Center, Inc.	MS	General Acute Care Hospital	$0	$42M
Mississippi Children's Home Society - Mypac	MS	Mental Illness Community Based Residential Treatment Facility	$0	$26.5M
Medical Foundation Of Central Mississippi, Inc.	MS	Internal Medicine Physician	$0	$7.5M
James Brown	MS	Retina Specialist (Ophthalmology) Physician	$5.4M	$8.9K
Michael Borne	MS	Retina Specialist (Ophthalmology) Physician	$4.5M	$1.8K
Mississippi Physicians, LLP	MS	Emergency Medicine Physician	$0	$4.2M
Mae Physicians Surgery Center, LLC	MS	Ambulatory Surgical Clinic/Center	$3.4M	$114.8K
Chelsea Cockrell	MS	Family Nurse Practitioner	$3M	$0
Mississippi Urology Outpatient Surgery Center, LLC	MS	Ambulatory Surgical Clinic/Center	$1.8M	$9.8K

Justin Baker — Billing Profile & Reimbursement Data

Sign up for Justin Baker — Billing Profile & Reimbursement Data policy alerts

Justin Baker — Billing Profile & Reimbursement Data

Sign up for Justin Baker — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References